82P Preliminary analysis of tislelizumab (TIS) and chemotherapy as neoadjuvant therapy for potentially resectable stage IIIA/IIIB non-small cell lung cancer (NSCLC)

• DOI: 10.1016/j.iotech.2022.100186
• Publication Date: 2022-12-09T10:08:30Z
• Authors: T. Wang; L. Li; L. Huang; J. Liu; D.D. Zhu; C. Qin; J. Dong; H. Deng; X. Zheng; L. Tian; L. Jiang; W. Wang; P. Zhou; M. Su; D. Pu; X. Cai; M. Feng; X. Ou; Y. Wang; Q. Zhou
• Keywords: Carboplatin; Neoadjuvant Therapy; Clinical endpoint; Chemoimmunotherapy

The benefit of neoadjuvant immunotherapy and chemotherapy in resectable NSCLC indicated that this combination therapy may provide more surgical opportunities survival benefits to potentially locally advanced NSCLC. Herein, we initiated a phase II study evaluate the feasibility plus stage IIIA/IIIB We planned recruit 33 patients (pts) with EGFR/ALK/ROS wild-type Eligible pts received 2 cycles chemoimmunotherapy (PD-1 inhibitor TIS, nab-paclitaxel, cisplatin/carboplatin) were reassessed for surgery. Thereafter, underwent surgery within 6 weeks continued TIS chemotherapy, followed by up 15 monotherapy. primary endpoint was R0 resection rate. Secondary endpoints major pathologic response (MPR), complete (pCR), disease-free survival, overall survival. From Jan 2021 Sep 2022, 18 enrolled (54.5%) completed (13 IIIA 5 IIIB disease). No treatment-related delay occurred. 17 (94.4%) successful (Table). Of who resection,6 (33.3%) achieved pCR 4 (22.2%) MPR, resulting an rate 55.6%. 3 had only 1% viable tumor cells specimen. (ORR) disease control (DCR) 88.9% (16/18) 100 % (18/18), respectively. Both clinical pathological downstaging occurred 16 (88.9%).Table: 82POutcomesResults, n (%, 95%CI); = 18Radiological responsePR16 (88.9, 65.29-98.62)SD2 (11.1, 1.38-34.71)ORR16 65.29-98.62)DCR18 (100, 81.5-100.0)Surgical resectionR017 (94.4, 72.71-99.86)R11 (5.6, 0.14-27.29)Downstaging rateclinical16 65.29-98.62)pathologic16 65.29-98.62)Pathologic response10 (55.6, 30.76-78.47)MPR4 (22.2, 6.41-47.64)pCR6 (33.3, 13.34-59.01) Open table new tab Neoadjuvant increased encouraging observed supports further investigation.